Rolf Ehrnström

Rolf Ehrnström is a Partner at Ventac Partners and the CEO of REomics AB, focusing on early-stage life sciences investments. He brings over 40 years of scientific and commercial expertise to his roles, having previously served as Chief Scientific Officer at Dako prior to its acquisition by Agilent. His executive background includes tenures as Vice President of R&D at Gyros AB, Science Director at Amersham Biosciences, and Chief Scientific Officer at Immunovia AB. Throughout his career across Scandinavia, Europe, and the United States, he has led research organizations with more than 200 staff members and managed complex company integrations. He currently holds board positions at Scandinavian ChemoTech and Gradientech, alongside maintaining a portfolio of 72,617 B-shares in related ventures. Ehrnström primarily focuses on advancing early-stage biotechnology, diagnostics, and personalized medicine startups through strategic research and development leadership.